KBLB OTCM· Kraig Biocraft Laboratories Inc.
FundamentalsNews digest Peer analysis
KBLB OTCM· Kraig Biocraft Laboratories Inc.
Earnings report Q3 2023

KBLB Reports No Revenue in Latest Quarter

Segments of Revenue

In the latest quarter, Kraig Biocraft Laboratories, Inc. (KBLB) reported no revenue from its business. This is consistent with the same quarter in the previous year, indicating no change in revenues between the two periods.


The company's financial performance in terms of revenue was stable, with no significant changes compared to the previous year. While the lack of revenue may be a concern, it is important to note that KBLB is a research and development-focused company, and revenue generation may not be the primary focus at this stage. Management may be prioritizing investments in research and development activities to drive future growth and innovation.


The lack of revenue in the latest quarter is a weakness for KBLB. It indicates that the company has not yet commercialized its products or services to generate substantial revenue. This could be a challenge for the company's financial sustainability and ability to fund ongoing operations. Additionally, the company's operating expenses remained high, resulting in a net loss for the quarter.


It is worth noting that KBLB's research and development expenses decreased by $22,989 compared to the same quarter in the previous year. This reduction in expenses may indicate cost management efforts by the company. However, it is important to monitor whether this reduction impacts the company's ability to innovate and develop new products.


KBLB reported no revenue in the latest quarter, consistent with the same quarter in the previous year. While this lack of revenue is a weakness for the company, it aligns with its research and development focus. The company's stable financial performance in terms of revenue indicates a continued emphasis on innovation and growth. However, the high operating expenses and net loss highlight the challenges KBLB faces in generating revenue and achieving financial sustainability. Investors should closely monitor the company's progress in commercializing its products and managing expenses.

Source documents

Form 10-Q  filed on Nov 13, 2023
95 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS missed by NaN%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.